Pharmacokinetic interactions of antiepileptic drugs.
The problem of antiepileptic drug interactions is significant in that many epileptic patients are treated with multiple drug therapy. Moreover, patients may also be receiving additional medication for other concurrent disorders. Most drug interactions are pharmacokinetic, involving changes in absorption, protein binding, metabolism, or excretion. As a result, plasma levels of the antiepileptic drug may decrease leading to exacerbation of seizures. Alternatively, plasma levels may rise resulting in toxic side effects. Similar changes may also occur with drugs given for other disorders. In this paper, possible mechanisms of drug interactions are discussed. This is followed by a description of clinically significant interactions involving phenytoin, carbamazepine, barbiturates, valproic acid, benzodiazepines, and succinimides. Potentially serious drug interactions may be minimized by using as few medications as possible and by regularly monitoring plasma levels of antiepileptic drugs.
D000818:Animals; D000927:Anticonvulsants / Q000008:administration & dosage*; D001463:Barbiturates / Q000008:administration & dosage / Q000097:blood; D001569:Benzodiazepines / Q000008:administration & dosage; D002220:Carbamazepine / Q000008:administration & dosage / Q000097:blood; D004347:Drug Interactions; D006801:Humans; D066298:In Vitro Techniques; D007408:Intestinal Absorption; D007668:Kidney / Q000378:metabolism; D007700:Kinetics; D010672:Phenytoin / Q000008:administration & dosage / Q000097:blood; D011485:Protein Binding; D051381:Rats; D013388:Succinimides / Q000008:administration & dosage; D014635:Valproic Acid / Q000008:administration & dosage / Q000097:blood
D000927:Anticonvulsants; D001463:Barbiturates; D013388:Succinimides; D001569:Benzodiazepines; D002220:Carbamazepine; D014635:Valproic Acid; D010672:Phenytoin